{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:47:54Z","timestamp":1785847674496,"version":"3.56.0"},"posted":{"date-parts":[[2026,6,18]]},"group-title":"In Review","reference-count":61,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,2]]},"abstract":"<title>Abstract<\/title>\n                <p>Advances with the 7\u2009+\u20093 regimen and liposomal CPX-351 have significantly improved the treatment of acute myeloid leukemia (AML); however, challenges like drug resistance and immune evasion persist. Despite the demonstrated potential of immunotherapy in treating several types of solid tumors, its impact on the treatment of AML remains limited. To address these challenges, we engineered an ultrasmall (~\u200915 nm) cytarabine (AraC)-based polymeric micelle nanocarrier (PAraC) for efficient AML cell uptake and bone marrow niche targeting. scRNA-seq and real-world dataset analysis identified upregulated TLR7\/8 in malignant AML cells, particularly after 7\u2009+\u20093 treatment, supporting the inclusion of the TLR7\/8 agonist R848 in our combination therapy. Our strategy integrates smart co-delivery of AraC, daunorubicin (Daun), and R848 using the PAraC platform. This triple nano-combination (PAraC\/Daun\/R848) demonstrated potent antitumor efficacy, outperforming CPX-351 and PAraC\/Daun in multiple leukemia models, including murine and patient-derived xenografts (PDX) AML models and AraC-resistant acute lymphoblastic leukemia (ALL) model. Notably, PAraC\/Daun\/R848 reversed immunosuppressive phenotypes seen with CPX-351 or PAraC\/Daun and induced robust leukemia cell maturation. With its modular design, efficient delivery, and remarkable preclinical performance, the PAraC platform holds immense promise for clinical translation, offering a new frontier for immunotherapeutic interventions in AML.<\/p>","DOI":"10.21203\/rs.3.rs-9901177\/v1","type":"posted-content","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T12:34:37Z","timestamp":1781786077000},"source":"Crossref","is-referenced-by-count":0,"title":["Dual-functional Nanocarrier for Improved Immunochemotherapy of Acute Myeloid Leukemia"],"prefix":"10.21203","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-949X","authenticated-orcid":false,"given":"Song","family":"Li","sequence":"first","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoya","family":"Wan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Wu","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9493-9961","authenticated-orcid":false,"given":"Yiqing","family":"Mu","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8916-0921","authenticated-orcid":false,"given":"Jing-Zhou","family":"Hou","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Sun","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3669-537X","authenticated-orcid":false,"given":"Wei","family":"Du","sequence":"additional","affiliation":[{"name":"University of Pittsburgh"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","volume-title":"Acute Myeloid Leukemia Treatment (PDQ\u00ae), in PDQ Cancer Information Summaries [Internet]","author":"Board PATE","year":"2023","unstructured":"Board, P.A.T.E., Acute Myeloid Leukemia Treatment (PDQ\u00ae), in PDQ Cancer Information Summaries [Internet]. 2023, National Cancer Institute (US)."},{"key":"ref2","volume-title":"Blueprints pediatrics","author":"Marino BS","year":"2013","unstructured":"Marino, B.S. and K.S. Fine, Blueprints pediatrics. Vol. 6. 2013: Lippincott Williams & Wilkins."},{"key":"ref3","author":"Surveillance Research Program NCI","unstructured":"Surveillance Research Program, N.C.I., SEER*Explorer: An interactive website for SEER cancer statistics 2024 Apr 17."},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3324\/haematol.2021.280161","article-title":"The \"7\u2009+\u20093\" regimen in acute myeloid leukemia","volume":"107","author":"Rowe JM","year":"2022","unstructured":"Rowe, J.M., The \"7\u2009+\u20093\" regimen in acute myeloid leukemia. Haematologica, 2022. 107(1): p. 3.","journal-title":"Haematologica"},{"issue":"2 Suppl 1","key":"ref5","first-page":"159","article-title":"Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C","volume":"14","author":"Plunkett W","year":"1987","unstructured":"Plunkett, W., et al., Saturation of ara-CTP accumulation during high-dose ara-C therapy: pharmacologic rationale for intermediate-dose ara-C. Semin Oncol, 1987. 14(2 Suppl 1): p. 159\u201366.","journal-title":"Semin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ejps.2017.06.030","article-title":"Ratiometric co-delivery of multiple chemodrugs in a single nanocarrier","volume":"107","author":"Chen C","year":"2017","unstructured":"Chen, C., et al., Ratiometric co-delivery of multiple chemodrugs in a single nanocarrier. Eur J Pharm Sci, 2017. 107: p. 16\u201323.","journal-title":"Eur J Pharm Sci"},{"issue":"26","key":"ref7","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia","volume":"36","author":"Lancet JE","year":"2018","unstructured":"Lancet, J.E., et al., CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia. J Clin Oncol, 2018. 36(26): p. 2684\u20132692.","journal-title":"J Clin Oncol"},{"key":"ref8","volume-title":"Hematology: Diagnosis and Treatment E-Book","author":"Hoffman R","year":"2013","unstructured":"Hoffman, R., et al., Hematology: Diagnosis and Treatment E-Book. 2013: Elsevier Health Sciences."},{"key":"ref9","volume-title":"Abeloff's Clinical Oncology E-Book","author":"Abeloff MD","year":"2008","unstructured":"Abeloff, M.D., et al., Abeloff's Clinical Oncology E-Book. 2008: Elsevier Health Sciences."},{"key":"ref10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon KM","year":"2018","unstructured":"Hargadon, K.M., C.E. Johnson, and C.J. Williams, Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. International immunopharmacology, 2018. 62: p. 29\u201339.","journal-title":"International immunopharmacology"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrclinonc.2016.25","article-title":"The future of cancer treatment: immunomodulation, CARs and combination immunotherapy","volume":"13","author":"Khalil DN","year":"2016","unstructured":"Khalil, D.N., et al., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature reviews Clinical oncology, 2016. 13(5): p. 273\u2013290.","journal-title":"Nature reviews Clinical oncology"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13045-017-0505-0","article-title":"Recent developments in immunotherapy of acute myeloid leukemia","volume":"10","author":"Lichtenegger FS","year":"2017","unstructured":"Lichtenegger, F.S., et al., Recent developments in immunotherapy of acute myeloid leukemia. Journal of hematology & oncology, 2017. 10(1): p. 142.","journal-title":"Journal of hematology & oncology"},{"key":"ref13","volume-title":"Adult Acute Myeloid Leukemia Treatment (PDQ\u00ae), in PDQ Cancer Information Summaries [Internet]","author":"Board PATE","year":"2020","unstructured":"Board, P.A.T.E., Adult Acute Myeloid Leukemia Treatment (PDQ\u00ae), in PDQ Cancer Information Summaries [Internet]. 2020, National Cancer Institute (US)."},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11095-019-2654-z","article-title":"Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia","volume":"36","author":"Chen KT","year":"2019","unstructured":"Chen, K.T., et al., Recent treatment advances and the role of nanotechnology, combination products, and immunotherapy in changing the therapeutic landscape of acute myeloid leukemia. Pharmaceutical research, 2019. 36(9): p. 125.","journal-title":"Pharmaceutical research"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1038\/s41375-018-0070-8","article-title":"Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes","volume":"32","author":"Daver N","year":"2018","unstructured":"Daver, N., et al., Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia, 2018. 32(5): p. 1094\u20131105.","journal-title":"Leukemia"},{"key":"ref16","volume-title":"Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists","author":"Bourquin C","year":"2019","unstructured":"Bourquin, C., A. Pommier, and C. Hotz, Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists. Pharmacological research, 2019."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12935-018-0515-1","article-title":"Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines","volume":"18","author":"Villam\u00f3n E","year":"2018","unstructured":"Villam\u00f3n, E., et al., Imiquimod inhibits growth and induces differentiation of myeloid leukemia cell lines. Cancer Cell Int, 2018. 18: p. 15.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"ref18","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1038\/leu.2014.293","article-title":"The role of TLR8 signaling in acute myeloid leukemia differentiation","volume":"29","author":"Ignatz-Hoover JJ","year":"2015","unstructured":"Ignatz-Hoover, J.J., et al., The role of TLR8 signaling in acute myeloid leukemia differentiation. Leukemia, 2015. 29(4): p. 918\u2013926.","journal-title":"Leukemia"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-009-0721-8","article-title":"The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells","volume":"59","author":"Smits EL","year":"2010","unstructured":"Smits, E.L., et al., The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother, 2010. 59(1): p. 35\u201346.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1038\/s41467-019-12657-w","article-title":"The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer","volume":"10","author":"Michaelis KA","year":"2019","unstructured":"Michaelis, K.A., et al., The TLR7\/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer. Nature communications, 2019. 10(1): p. 4682.","journal-title":"Nature communications"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3389\/fimmu.2016.00390","article-title":"The Role of Toll-Like Receptors in Hematopoietic Malignancies","volume":"7","author":"Monlish DA","year":"2016","unstructured":"Monlish, D.A., S.T. Bhatt, and L.G. Schuettpelz, The Role of Toll-Like Receptors in Hematopoietic Malignancies. Front Immunol, 2016. 7: p. 390.","journal-title":"Front Immunol"},{"key":"ref22","author":"Brenner AK","year":"2019","unstructured":"Brenner, A.K. and \u00d8. Bruserud, Functional Toll-Like Receptors (TLRs) Are Expressed by a Majority of Primary Human Acute Myeloid Leukemia Cells and Inducibility of the TLR Signaling Pathway Is Associated with a More Favorable Phenotype. Cancers (Basel), 2019. 11(7)."},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","article-title":"Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity","volume":"176","author":"Galen P","year":"2019","unstructured":"van Galen, P., et al., Single-cell RNA-seq reveals AML hierarchies relevant to disease progression and immunity. Cell, 2019. 176(6): p. 1265\u20131281. e24.","journal-title":"Cell"},{"issue":"14","key":"ref24","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: journey inside the cell","volume":"46","author":"Behzadi S","year":"2017","unstructured":"Behzadi, S., et al., Cellular uptake of nanoparticles: journey inside the cell. Chem Soc Rev, 2017. 46(14): p. 4218\u20134244.","journal-title":"Chem Soc Rev"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"101692","DOI":"10.1016\/j.mtcomm.2020.101692","article-title":"Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components","volume":"25","author":"Augustine R","year":"2020","unstructured":"Augustine, R., et al., Cellular uptake and retention of nanoparticles: Insights on particle properties and interaction with cellular components. Materials Today Communications, 2020. 25: p. 101692.","journal-title":"Materials Today Communications"},{"key":"ref26","author":"Milne TA","year":"2017","unstructured":"Milne, T.A., Mouse models of MLL leukemia: recapitulating the human disease. Blood, The Journal of the American Society of Hematology, 2017. 129(16): p. 2217\u20132223."},{"key":"ref27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.2147\/IJN.S229576","article-title":"Pulmonary-Affinity Paclitaxel Polymer Micelles in Response to Biological Functions of Ambroxol Enhance Therapeutic Effect on Lung Cancer","volume":"15","author":"He W","year":"2020","unstructured":"He, W., et al., Pulmonary-Affinity Paclitaxel Polymer Micelles in Response to Biological Functions of Ambroxol Enhance Therapeutic Effect on Lung Cancer. Int J Nanomedicine, 2020. 15: p. 779\u2013793.","journal-title":"Int J Nanomedicine"},{"issue":"4 Pt 2","key":"ref28","first-page":"375","article-title":"Myeloid leukemia C-1498 as a screen for cancer chemotherapeutic agents","volume":"26","author":"Bradner WT","year":"1966","unstructured":"Bradner, W.T. and M.H. Pindell, Myeloid leukemia C-1498 as a screen for cancer chemotherapeutic agents. Cancer Res, 1966. 26(4 Pt 2): p. 375\u201390.","journal-title":"Cancer Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41232-020-00127-6","article-title":"Migration arrest of chemoresistant leukemia cells mediated by MRTF-SRF pathway","volume":"40","author":"Morimatsu M","year":"2020","unstructured":"Morimatsu, M., et al., Migration arrest of chemoresistant leukemia cells mediated by MRTF-SRF pathway. Inflamm Regen, 2020. 40: p. 15.","journal-title":"Inflamm Regen"},{"issue":"8","key":"ref30","first-page":"1545","article-title":"PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model","volume":"114","author":"Zhang L","year":"2009","unstructured":"Zhang, L., T.F. Gajewski, and J. Kline, PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood, The Journal of the American Society of Hematology, 2009. 114(8): p. 1545\u20131552.","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"6","key":"ref31","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S0092-8674(00)81269-6","article-title":"An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes","volume":"85","author":"Corral J","year":"1996","unstructured":"Corral, J., et al., An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes. Cell, 1996. 85(6): p. 853\u201361.","journal-title":"Cell"},{"issue":"16","key":"ref32","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1182\/blood-2016-10-691428","article-title":"Mouse models of MLL leukemia: recapitulating the human disease","volume":"129","author":"Milne TA","year":"2017","unstructured":"Milne, T.A., Mouse models of MLL leukemia: recapitulating the human disease. Blood, 2017. 129(16): p. 2217\u20132223.","journal-title":"Blood"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani A","year":"2002","unstructured":"Mantovani, A., et al., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol, 2002. 23(11): p. 549\u201355.","journal-title":"Trends Immunol"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1038\/s41467-021-27300-w","article-title":"Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia","volume":"12","author":"Wu L","year":"2021","unstructured":"Wu, L., et al., Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia. Nat Commun, 2021. 12(1): p. 6936.","journal-title":"Nat Commun"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc.2017.103","article-title":"Differentiation therapy revisited","volume":"18","author":"Th\u00e9 H","year":"2018","unstructured":"de Th\u00e9, H., Differentiation therapy revisited. Nat Rev Cancer, 2018. 18(2): p. 117\u2013127.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"11344","DOI":"10.1038\/s41598-022-15520-z","article-title":"Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis","volume":"12","author":"Tomic B","year":"2022","unstructured":"Tomic, B., et al., Cytarabine-induced differentiation of AML cells depends on Chk1 activation and shares the mechanism with inhibitors of DHODH and pyrimidine synthesis. Scientific Reports, 2022. 12(1): p. 11344.","journal-title":"Scientific Reports"},{"key":"ref37","author":"Ancker W","year":"2009","unstructured":"van den Ancker, W., et al., Maturation by Toll Like Receptor Ligand R848 Improves the Uptake of Apoptotic Leukemic Cells by Monocyte Derived Dendritic Cells. Blood, 2009. 114(22): p. 2075."},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions","volume":"21","author":"Yi M","year":"2022","unstructured":"Yi, M., et al., Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer, 2022. 21(1): p. 28.","journal-title":"Mol Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"928369","DOI":"10.3389\/fphar.2022.928369","article-title":"Combinatorial Strategies With PD-1\/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes","volume":"13","author":"Zheng D","year":"2022","unstructured":"Zheng, D., et al., Combinatorial Strategies With PD-1\/PD-L1 Immune Checkpoint Blockade for Breast Cancer Therapy: Mechanisms and Clinical Outcomes. Front Pharmacol, 2022. 13: p. 928369.","journal-title":"Front Pharmacol"},{"issue":"22","key":"ref40","doi-asserted-by":"crossref","first-page":"6353","DOI":"10.1158\/0008-5472.CAN-16-3167","article-title":"PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer","volume":"77","author":"Kansy BA","year":"2017","unstructured":"Kansy, B.A., et al., PD-1 Status in CD8(+) T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Res, 2017. 77(22): p. 6353\u20136364.","journal-title":"Cancer Res"},{"issue":"1","key":"ref41","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan D","year":"2023","unstructured":"Fan, D., et al., Nanomedicine in cancer therapy. Signal Transduction and Targeted Therapy, 2023. 8(1): p. 293.","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"17","key":"ref42","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.3390\/ijms22179587","article-title":"Cancer-nano-interaction: From cellular uptake to mechanobiological responses","volume":"22","author":"Sohrabi Kashani A","year":"2021","unstructured":"Sohrabi Kashani, A. and M. Packirisamy, Cancer-nano-interaction: From cellular uptake to mechanobiological responses. International Journal of Molecular Sciences, 2021. 22(17): p. 9587.","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","article-title":"Engineering precision nanoparticles for drug delivery","volume":"20","author":"Mitchell MJ","year":"2021","unstructured":"Mitchell, M.J., et al., Engineering precision nanoparticles for drug delivery. Nature reviews drug discovery, 2021. 20(2): p. 101\u2013124.","journal-title":"Nature reviews drug discovery"},{"issue":"6","key":"ref44","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1039\/D2LC00799A","article-title":"Nanoparticle protein corona: from structure and function to therapeutic targeting","volume":"23","author":"Bashiri G","year":"2023","unstructured":"Bashiri, G., et al., Nanoparticle protein corona: from structure and function to therapeutic targeting. Lab on a Chip, 2023. 23(6): p. 1432\u20131466.","journal-title":"Lab on a Chip"},{"issue":"4","key":"ref45","first-page":"e1788","article-title":"Influence of surface chemistry and morphology of nanoparticles on protein corona formation","volume":"14","author":"Bilardo R","year":"2022","unstructured":"Bilardo, R., et al., Influence of surface chemistry and morphology of nanoparticles on protein corona formation. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022. 14(4): p. e1788.","journal-title":"Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology"},{"issue":"19","key":"ref46","doi-asserted-by":"crossref","first-page":"2307940","DOI":"10.1002\/advs.202307940","article-title":"In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy","volume":"11","author":"Luo Z","year":"2024","unstructured":"Luo, Z., et al., In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy. Advanced Science, 2024. 11(19): p. 2307940.","journal-title":"Advanced Science"},{"key":"ref47","first-page":"75","article-title":"Acute leukemia clinical presentation","author":"Hamid GA","year":"2013","unstructured":"Hamid, G.A., Acute leukemia clinical presentation. Leukemia, 2013. 75.","journal-title":"Leukemia"},{"key":"ref48","first-page":"4","article-title":"The dentist\u2019s role in improving the life\u2019s quality of children with leukemia","volume":"3","author":"Varkesh H","year":"2013","unstructured":"Varkesh, H., et al., The dentist\u2019s role in improving the life\u2019s quality of children with leukemia. liver, 2013. 3: p. 4.","journal-title":"liver"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"100773","DOI":"10.1016\/j.blre.2020.100773","article-title":"Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved","volume":"47","author":"Shallis RM","year":"2021","unstructured":"Shallis, R.M., et al., Myeloid sarcoma, chloroma, or extramedullary acute myeloid leukemia tumor: a tale of misnomers, controversy and the unresolved. Blood reviews, 2021. 47: p. 100773.","journal-title":"Blood reviews"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2478\/raon-2019-0014","article-title":"Radiological and clinical patterns of myeloid sarcoma","volume":"53","author":"Meyer H-J","year":"2019","unstructured":"Meyer, H.-J., et al., Radiological and clinical patterns of myeloid sarcoma. Radiology and Oncology, 2019. 53(2): p. 213\u2013218.","journal-title":"Radiology and Oncology"},{"issue":"11","key":"ref51","doi-asserted-by":"crossref","first-page":"e1230578","DOI":"10.1080\/2162402X.2016.1230578","article-title":"TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function","volume":"5","author":"Spinetti T","year":"2016","unstructured":"Spinetti, T., et al., TLR7-based cancer immunotherapy decreases intratumoral myeloid-derived suppressor cells and blocks their immunosuppressive function. Oncoimmunology, 2016. 5(11): p. e1230578.","journal-title":"Oncoimmunology"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1038\/s41467-021-26849-w","article-title":"Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy","volume":"12","author":"Ngo S","year":"2021","unstructured":"Ngo, S., et al., Acute myeloid leukemia maturation lineage influences residual disease and relapse following differentiation therapy. Nature Communications, 2021. 12(1): p. 6546.","journal-title":"Nature Communications"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00262-009-0721-8","article-title":"The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells","volume":"59","author":"Smits EL","year":"2010","unstructured":"Smits, E.L., et al., The Toll-like receptor 7\/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunology, Immunotherapy, 2010. 59: p. 35\u201346.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"10","key":"ref54","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/ni1006-1029","article-title":"On regulation of phagosome maturation and antigen presentation","volume":"7","author":"Blander JM","year":"2006","unstructured":"Blander, J.M. and R. Medzhitov, On regulation of phagosome maturation and antigen presentation. Nature immunology, 2006. 7(10): p. 1029\u20131035.","journal-title":"Nature immunology"},{"issue":"1","key":"ref55","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.0105-2896.2005.00301.x","article-title":"Cross-presentation: underlying mechanisms and role in immune surveillance","volume":"207","author":"Rock KL","year":"2005","unstructured":"Rock, K.L. and L. Shen, Cross-presentation: underlying mechanisms and role in immune surveillance. Immunological reviews, 2005. 207(1): p. 166\u2013183.","journal-title":"Immunological reviews"},{"issue":"3","key":"ref56","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y","year":"2020","unstructured":"Han, Y., D. Liu, and L. Li, PD-1\/PD-L1 pathway: current researches in cancer. American journal of cancer research, 2020. 10(3): p. 727.","journal-title":"American journal of cancer research"},{"issue":"4","key":"ref57","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/ph14040288","article-title":"Is there a place for PD-1-PD-L blockade in acute myeloid leukemia?","volume":"14","author":"Jimbu L","year":"2021","unstructured":"Jimbu, L., et al., Is there a place for PD-1-PD-L blockade in acute myeloid leukemia? Pharmaceuticals, 2021. 14(4): p. 288.","journal-title":"Pharmaceuticals"},{"issue":"8","key":"ref58","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1007\/s00262-023-03454-y","article-title":"Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent\u2009+\u2009CAG regimen in patients with relapsed\/refractory acute myeloid leukemia","volume":"72","author":"Gao X-N","year":"2023","unstructured":"Gao, X.-N., et al., Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent\u2009+\u2009CAG regimen in patients with relapsed\/refractory acute myeloid leukemia. Cancer Immunology, Immunotherapy, 2023. 72(8): p. 2769\u20132782.","journal-title":"Cancer Immunology, Immunotherapy"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"6936","DOI":"10.1038\/s41467-021-27300-w","article-title":"Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia","volume":"12","author":"Wu L","year":"2021","unstructured":"Wu, L., et al., Quinacrine-CASIN combination overcomes chemoresistance in human acute lymphoid leukemia. Nature Communications, 2021. 12(1): p. 6936.","journal-title":"Nature Communications"},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.7150\/thno.38287","article-title":"High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy","volume":"10","author":"Sun J","year":"2020","unstructured":"Sun, J., et al., High Loading of Hydrophobic and Hydrophilic Agents via Small Immunostimulatory Carrier for Enhanced Tumor Penetration and Combinational Therapy. Theranostics, 2020. 10(3): p. 1136\u20131150.","journal-title":"Theranostics"},{"issue":"19","key":"ref61","doi-asserted-by":"crossref","first-page":"e2307940","DOI":"10.1002\/advs.202307940","article-title":"Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy","volume":"11","author":"Luo Z","year":"2024","unstructured":"Luo, Z., et al., In Situ Formation of Fibronectin-Enriched Protein Corona on Epigenetic Nanocarrier for Enhanced Synthetic Lethal Therapy. Adv Sci (Weinh), 2024. 11(19): p. e2307940.","journal-title":"Adv Sci (Weinh)"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9901177\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9901177\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T12:27:50Z","timestamp":1785846470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-9901177\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":61,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-9901177\/v1","relation":{},"subject":[],"published":{"date-parts":[[2026,6,18]]},"subtype":"preprint"}}